Product nameAnti-CD45.1 antibody [A20] (Cy5 ®)
See all CD45.1 primary antibodies
DescriptionMouse monoclonal [A20] to CD45.1 (Cy5 ®)
ConjugationCy5 ®. Ex: 650nm, Em: 667nm
Specificityab24982 recognizes all mouse leukocytes expressing the CD45.1 allotype.
Tested applicationsSuitable for: Flow Cyt, ICC/IF, IPmore details
Species reactivityReacts with: Mouse
The details of the immunogen for this antibody are not available.
General notesThis product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5,268,486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.1% Sodium azide
Concentration information loading...
Light chain typekappa
- Anti-CD45.1 antibody [A20] (PerCP/Cy5.5®) (ab210237)
- Anti-CD45.1 antibody [A20] (FITC) (ab24917)
- Anti-CD45.1 antibody [A20] (Biotin) (ab25011)
- Anti-CD45.1 antibody [A20] (Phycoerythrin) (ab25012)
- Anti-CD45.1 antibody [A20] (ab25078)
- Anti-CD45.1 antibody [A20] (Allophycocyanin) (ab25348)
- Anti-CD45.1 antibody [A20] (PE/Cy5®) (ab25349)
- Anti-CD45.1 antibody [A20] (Allophycocyanin/Cy7 ®) (ab46823)
Our Abpromise guarantee covers the use of ab24982 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 0.2µg for 106 cells.
ab154446 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|ICC/IF||Use at an assay dependent concentration.|
|IP||Use at an assay dependent concentration.|
RelevanceCD45 is an essential regulator of leukocyte activation and development, and is now known to be a protein tyrosine phosphatase, e.g. CD45 is able to dephosphorylate the Src family of protein kinases. This activity is now known to be required for signal transduction induced by T and B cell antigen receptor engagement, cytokine signaling and Fc receptor stimulation. The functional state of CD45 also has a pronounced effect on lymphocyte development. CD45 exists in multiple forms, such as the restricted variants and as allelic forms CD45.1/Ly5.1 and CD45.2/Ly5.2. The former arises as a result of alternative splicing of different exons. The specificity of antibodies to CD45.1 and CD45.2 has been exploited in studies in which resolution of donor and recipient cells is essential, such as in gene therapy or bone marrow transplantation.
Cellular localizationType I membrane protein.
- B220 antibody
- CD45 antibody
- CD45 antigen antibody
ab24982 has not yet been referenced specifically in any publications.